Welcome to our dedicated page for Incyte SEC filings (Ticker: INCY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Incyte Corporation's SEC filings document a Nasdaq-listed biopharmaceutical issuer with common stock trading under INCY and product franchises in hematology, oncology, and inflammation and autoimmunity. Form 8-K reports cover operating results, product sales trends for Jakafi and Opzelura, financial guidance, pipeline updates, and regulatory correspondence affecting drug applications.
Proxy and current-report filings also disclose board and executive changes, officer appointments, equity compensation, shareholder voting matters, executive pay, governance practices, and registered security information. These filings frame Incyte's capital structure, leadership oversight, commercial portfolio, clinical-development programs, and regulatory risks.
INCYTE CORP executive Pablo J. Cagnoni, President and Global Head of R&D, reported two F-code tax-withholding dispositions of common stock tied to settlements of restricted stock units and earned performance shares, totaling 22,919 shares at prices of $114.88 and $115.09 per share. After these withholdings, he directly holds 217,929.0000 shares of common stock, and his reported holdings include 169,797 shares issuable from unvested restricted stock units and earned performance shares.
INCYTE CORP EVP & Chief Scientific Officer Patrick A Mayes reported automatic tax-withholding dispositions totaling 1,949 shares of common stock on July 14–15, 2026, to satisfy RSU-related tax obligations. Following these withholdings, he directly holds 57,712 shares, including 53,621 issuable from unvested restricted stock units.
INCYTE CORP Principal Accounting Officer Tray Thomas reported two tax-withholding dispositions of common stock related to restricted stock unit settlements, totaling 1,790 shares on July 14–15, 2026. After these withholdings, Thomas holds 18,865 shares directly, including 10,236 shares issuable from unvested restricted stock units.
INCYTE CORP executive Steven H. Stein, CMO & Head of Late-Stage Development, reported multiple common stock transactions. On July 15, 2026, he completed an open-market sale of 28,237 shares at $113.05 per share. On July 14 and 15, a total of 24,918 shares were disposed of through automatic tax withholding tied to the settlement of restricted stock units (RSUs) and earned performance shares, rather than discretionary market sales. Following the reported open-market sale, he reported holding 26,083 shares of common stock directly, and his beneficial ownership figure includes 19,540 shares issuable from unvested RSUs and earned performance-share awards.
Incyte Corp executive Mohamed Khairie, EVP and Head of U.S. Commercial, reported a tax-related share disposition. On 2026-07-15, 1,099 common shares were automatically withheld by the company at $115.09 per share to satisfy RSU tax withholding obligations. Following this withholding, Khairie holds 65,033 shares directly, including 63,940 shares issuable from unvested restricted stock units.
A holder of INCY common stock filed a notice to sell 28,237 common shares through Morgan Stanley Smith Barney LLC on NASDAQ, with an associated value of $3,192,254.97 and an intended sale date of July 15, 2026. The securities to be sold consist of performance shares and restricted stock awards acquired from the issuer in July 2026, and the filing cites 199,782,155 common shares outstanding as context.
INCYTE CORP executive Patrick A. Mayes had 350 shares of common stock withheld by the company to cover tax obligations tied to restricted stock units. The withholding price was $116.86 per share. After this non-market tax-withholding event, he directly holds 59,661 shares of common stock.
A footnote also notes 58,730 additional shares are issuable from unvested restricted stock units, which are not yet settled into common stock.
INCYTE CORP Principal Accounting Officer Tray Thomas had 477 shares of common stock withheld on a recent restricted stock unit settlement. These shares were automatically retained by the company to cover tax withholding obligations, not sold on the open market. After this tax-withholding disposition, Thomas directly holds 20,655 shares, including 14,128 shares tied to unvested restricted stock units.
INCYTE CORP Chief Executive Officer and President William Meury reported a routine tax-related share disposition. On July 2, 2026, 4,779 shares of common stock were withheld at $116.86 per share to cover tax obligations tied to previously granted RSUs and earned performance shares.
After this automatic withholding, Meury directly owns 156,322 shares of common stock. Footnotes state this total includes 152,076 shares issuable from restricted stock units and earned performance shares that have not yet vested, highlighting that most of his reported position remains unvested equity awards rather than freely tradable shares.